Alprazolam
Alprazolam, Xanax (alprazolam) is a small molecule pharmaceutical. Alprazolam was first approved as Xanax on 1982-01-01. It is used to treat agoraphobia, depressive disorder, and panic disorder in the USA. It is known to target gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit alpha-5, and gamma-aminobutyric acid receptor subunit alpha-3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Xanax (generic drugs available since 1993-10-19, discontinued: Niravam)
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alprazolam | ANDA | 2027-07-31 |
| alprazolam c-iv | ANDA | 2023-05-08 |
| alprazolam intensol | 2006-01-04 | |
| alprazolam xr | NDA authorized generic | 2011-04-12 |
| gabazolamine | unapproved drug other | 2011-08-18 |
| gabazolamine-0.5 | unapproved drug other | 2011-08-01 |
| niravam | New Drug Application | 2011-04-19 |
| sentrazolam am | unapproved drug other | 2011-08-01 |
| xanax | New Drug Application | 2023-01-18 |
| xanax xr | New Drug Application | 2010-04-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
101 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 28 | — | — | 1 | — | 29 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 5 | 3 | 2 | 4 | 1 | 15 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | 1 | 1 | — | 7 | — | 9 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 3 | 1 | 1 | 2 | — | 6 |
| Drinking behavior | D004327 | EFO_0004315 | — | 1 | — | — | 1 | — | 2 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | 1 | — | 1 |
| Psychomotor disorders | D011596 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | HP_0002069 | G40.4 | — | — | 2 | — | — | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | 3 | — | — | — | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 1 | — | — | 1 | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 1 | — | — | — | 2 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | 1 | 1 | — | — | — | 1 |
| Dental anxiety | D016854 | — | — | — | 1 | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | 1 | — | — | — | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | 1 | — | — | — | 1 |
| St elevation myocardial infarction | D000072657 | — | — | 1 | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Food-drug interactions | D018565 | — | — | 1 | — | — | — | — | 1 |
| Recreational drug use | D000084783 | — | — | 1 | — | — | — | — | 1 |
| Delirium | D003693 | — | R41.0 | 1 | — | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Huntington disease | D006816 | Orphanet_399 | G10 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | 1 | — | — | — | — | 1 |
| Driving under the influence | D000066448 | — | — | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Coronary angiography | D017023 | — | — | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alprazolam |
| INN | alprazolam |
| Description | Alprazolam is a member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug. It has a role as an anxiolytic drug, an anticonvulsant, a muscle relaxant, a sedative, a GABA agonist and a xenobiotic. It is a triazolobenzodiazepine and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | Benzodiazepine |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2 |
Identifiers
| PDB | — |
| CAS-ID | 28981-97-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL661 |
| ChEBI ID | 2611 |
| PubChem CID | 2118 |
| DrugBank | DB00404 |
| UNII ID | YU55MQ3IZY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BRD4
BRD4
Organism
Homo sapiens
Gene name
BRD4
Gene synonyms
HUNK1
NCBI Gene ID
Protein name
bromodomain-containing protein 4
Protein synonyms
chromosome-associated protein, female sterile homeotic related gene 4, mitotic chromosome-associated protein, Protein HUNK1
Uniprot ID
Mouse ortholog
Brd4 (57261)
bromodomain-containing protein 4 (Q9ESU6)
Variants
No data
Financial
Estimated US medical usage
Alprazolam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,337 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alprazolam, Alprazolam c-iv, Xanax
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
53,940 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use